An Ivy Center clinical research nurse administers SonALAsense's proprietary formulation of 5-aminolevulinic acid (Sonala-001) to the first patient enrolled in a drug-device combination study for ...
Glioblastoma, also known as glioblastoma multiforme (GBM) is a particularly insidious and deadly form of brain cancer. The typical duration of survival following diagnosis is 12–15 months, with fewer ...
OAKLAND, Calif.--(BUSINESS WIRE)--SonALAsense, a pioneer in the development of SONALA-001 and sonodynamic therapy (SDT), a new drug-device combination developed to manage deadly cancers so patients ...
OAKLAND, Calif.--(BUSINESS WIRE)--SonALAsense, a pioneer in the development of non-invasive Sonodynamic Therapy (SDT) using SONALA-001, today announced that the United States Food and Drug ...
Ivy Center's clinical trial of sonodynamic therapy uses Insightec’s magnetic resonance-guided focused ultrasound (MRgFUS) technology in combination with SonALAsense’s proprietary intravenous ...
OAKLAND, Calif. — SonALAsense, a pioneer in the development of non-invasive Sonodynamic Therapy (SDT) using SONALA-001 (aminolevulinic acid HCl) in combination with Insightec’s Exablate 4000 Type-2 ...
SonALAsense has announced that the first cohort in Sonodynamic Therapy (SDT)-202 was fully enrolled. SDT-202 is an open-label, dose-escalation trial of SDT in recurrent glioblastoma (rGBM). The ...
The Nature Index tracks primary research articles from 178 applied, health, natural and social sciences journals, across many different publishers, chosen by an independent group of researchers. The ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The three-year-old Oakland ...
Sonalasense Inc., a company working in the field of sonodynamic therapy, is collaborating with the Ivy Brain Tumor Center at Barrow Neurological Institute to conduct a first-in-human clinical trial of ...
Company has received Safe to Proceed letters from FDA for two clinical trials in life-threatening brain tumors, DIPG trial is open and actively recruiting, it has expanded its executive leadership ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results